Lv11
10 积分 2022-08-30 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1小时前
已完结
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial
6天前
已完结
Neoadjuvant chemotherapy with mFOLFOXIRI without Routine use of radiotherapy for locally advanced rectal cancer
10天前
已完结
结直肠癌中国改良三药FOLFOXIRI方案临床应用专家共识（2026版）
10天前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
10天前
已完结
Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2)
10天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
19天前
已完结
Review on natural killer/T-cell lymphoma
24天前
已完结
免疫检查点抑制剂相关肺炎诊治和管理专家共识（2025）
25天前
已完结
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
30天前
已完结
皖公网安备34019202002308
